IMR Press / EJGO / Volume 19 / Issue 2 / pii/1998133

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Case Report

Expression of p53 protein in borderline epithelial ovarian tumors: a clinicopathologic study of 39 cases

Show Less
1 Service de Gynécologie, h?pital Bichat-Claude Bernard, France
2 Service d’Anatomie Pathologique, h?pital Bichat-Claude Bernard, France
3 Delegation à l’ évaluation médicale, Assistance Publique des h?pitaux de Paris, France
4 Laboratoire de Biologie Cellulaire, Faculté Xavier Bichat, France
Eur. J. Gynaecol. Oncol. 1998, 19(2), 144–149;
Published: 10 April 1998
Abstract

Objective: To evaluate the expression of p53 protein in borderline ovarian tumors and its correlations with the clinicopathological parameters. Study design: p53 protein was detected by immunoperoxidase in 79 ovarian tumors (39 borderline, 20 malignant, 20 benign). p53expression was compared to histological type, FIGO stage, age, presence of ascites: recurrence and patient smvıval. Results: The median value of quantitative p53 immunopositivity was: 0.80 ± 0.42 in ovaıan cancers, 0 ± 0.24 m borderlme tumors and 0 ± 0.16 in benign tumors (p = 0.001). In borderline tumors, no correlation existed between p53 expression and the histological or clinical parameters. In malignant tumors, no correlation existed between the expression of p53 and patient survival. Conclusion: We found no correlation between p53 immunopositivity and clinicopathological parameters in carcinomas and bor­derline tumors of the ovary. p53 immunopositivity may help in distinguishing borderline tumors from ovarian cancers.

Keywords
p53 protein
Immunohistochemistry
Borderline ovarian tumor
Ovarian cancer
Benign ovarian tumor
Share
Back to top